000597 东北制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.5164.7937.9517.5098.049
总资产报酬率 ROA (%)0.6341.9032.7582.4652.595
投入资产回报率 ROIC (%)0.8352.5033.5693.3053.570

边际利润分析
销售毛利率 (%)32.41837.27538.73540.67638.955
营业利润率 (%)3.0684.4407.7016.0447.905
息税前利润/营业总收入 (%)3.7134.5657.5675.5596.055
净利润/营业总收入 (%)1.9143.0795.6424.5614.054

收益指标分析
经营活动净收益/利润总额(%)141.911132.087103.359118.58471.086
价值变动净收益/利润总额(%)0.2482.6730.8691.7630.000
营业外收支净额/利润总额(%)-2.601-2.8992.719-2.059-32.528

偿债能力分析
流动比率 (X)1.1421.1481.0471.0220.942
速动比率 (X)0.9590.9680.8870.8800.797
资产负债率 (%)58.37056.01561.44666.22565.871
带息债务/全部投入资本 (%)41.99638.10246.18154.84748.864
股东权益/带息债务 (%)127.282148.949104.38476.26595.515
股东权益/负债合计 (%)69.82376.59459.95149.31650.119
利息保障倍数 (X)5.14118.231-21.652-15.28767.412

营运能力分析
应收账款周转天数 (天)106.34093.93190.51382.73478.069
存货周转天数 (天)101.206101.622105.26095.13182.602